Marianne de Backer
Chief Executive Officer chez VIR BIOTECHNOLOGY, INC.
Fortune : 7 M $ au 31/03/2024
Profil
Marianne de Backer is currently the Chief Executive Officer & Director at Vir Biotechnology, Inc. and the President & Chief Executive Officer at Agenovir Corp.
She also holds positions as a Director at EcoHealth Alliance, Inc., Gladstone Foundation (CA), and Vividion Therapeutics, Inc. In her former roles, Dr. de Backer served as an Independent Director at Arrowhead Pharmaceuticals, Inc. from 2019 to 2023.
She was also a Director at Asklepios BioPharmaceutical, Inc. and BlueRock Therapeutics LP.
From 1991 to 2019, she worked at Johnson & Johnson as the Vice President-Mergers & Acquisitions Operations.
Additionally, she served as the EVP & Head-Global Business Development & Licensing at Bayer AG from 2019 to 2023.
Dr. de Backer obtained her graduate and doctorate degrees from Ghent University.
She also holds a graduate degree from Vrije Universiteit Brussel and an MBA from Rotterdam School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VIR BIOTECHNOLOGY, INC.
0,50% | 03/04/2024 | 678 457 ( 0,50% ) | 7 M $ | 31/03/2024 |
KRONOS BIO INC
0,00% | 22/06/2023 | 2 750 ( 0,00% ) | 3 575 $ | 31/03/2024 |
Postes actifs de Marianne de Backer
| Sociétés | Poste | Début |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Chief Executive Officer | 03/04/2023 |
EcoHealth Alliance, Inc.
 EcoHealth Alliance, Inc. Miscellaneous Commercial ServicesCommercial Services EcoHealth Alliance, Inc. operates a not for profit organization. It protects the health of people, animals, and the environment. Its programs include rift valley fever, predict, health and policy initiatives, monitoring the deadly Nipah virus, emerging disease hotspots, project deep forest, ecohealthy pets, global wildlife trade, and economics of emerging infectious diseases. The company is headquartered in New York, NY. | Director/Board Member | - |
| Gladstone Foundation (CA) | Director/Board Member | - |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Director/Board Member | - |
Agenovir Corp.
 Agenovir Corp. Pharmaceuticals: MajorHealth Technology Agenovir Corp. provides research and developing novel antiviral therapeutics for diseases. The company was founded by Bruce Hironaka and Stephen R. Quake and is headquartered in San Francisco, CA. | Chief Executive Officer | - |
Anciens postes connus de Marianne de Backer
| Sociétés | Poste | Fin |
|---|---|---|
| KRONOS BIO, INC. | Director/Board Member | 23/06/2023 |
| ARROWHEAD PHARMACEUTICALS, INC. | Director/Board Member | 02/04/2023 |
| BAYER AG | Corporate Officer/Principal | 01/03/2023 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01/01/2019 |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Marianne de Backer
| Ghent University | Doctorate Degree |
| Vrije Universiteit Brussel | Graduate Degree |
| Rotterdam School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| BAYER AG | Health Technology |
| VIR BIOTECHNOLOGY, INC. | Health Technology |
| KRONOS BIO, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Asklepios BioPharmaceutical, Inc.
 Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. | Health Technology |
EcoHealth Alliance, Inc.
EcoHealth Alliance, Inc. Miscellaneous Commercial ServicesCommercial Services EcoHealth Alliance, Inc. operates a not for profit organization. It protects the health of people, animals, and the environment. Its programs include rift valley fever, predict, health and policy initiatives, monitoring the deadly Nipah virus, emerging disease hotspots, project deep forest, ecohealthy pets, global wildlife trade, and economics of emerging infectious diseases. The company is headquartered in New York, NY. | Commercial Services |
| Gladstone Foundation (CA) | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
Agenovir Corp.
Agenovir Corp. Pharmaceuticals: MajorHealth Technology Agenovir Corp. provides research and developing novel antiviral therapeutics for diseases. The company was founded by Bruce Hironaka and Stephen R. Quake and is headquartered in San Francisco, CA. | Health Technology |
BlueRock Therapeutics LP
 BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company based in Cambridge, MA. The private company is focused on creating cellular medicines to reverse devastating diseases such as neurological, cardiovascular, immunological, and ophthalmic diseases. BlueRock Therapeutics's lead clinical program, Bemdaneprocel, is in phase I clinical trials for Parkinson's disease. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. The company was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. | Commercial Services |
